Our Supporters
COMMUNITY
Mr. Branson
Kombi Sports, Montreal, Québec
“When I found the MPN Clinic at the Jewish General Hospital in Montreal I was someone who had been diagnosed with PV and wanted patients with similar disorders to get testing and treatment by Hematologists who were familiar with these blood disorders. Now this group of Hematologists together with others across Canada have formed the Canadian MPN Group to improve the care and research in patients with MPN. Through the leadership of Dr. Vikas Gupta and the collaboration of the other Hematologists forming the nucleus of Leadership and Governance for the Group it is expected that diagnosis, treatment and eventual cure will be made available to all including education and information of this little known but ever prevalent disease.”
Mr. Solsberg
Immediate Past President and CEO, BMO Financial Group
Toronto, Ontario
“Rare diseases such as Myeloproliferative Neoplasms can be extremely challenging. Very often, many patients do not have access to appropriate experts for seeking advice regarding diagnosis and treatment. We congratulate Canadian MPN group on this important initiative of bringing health care professionals interested in care of MPNs together, and improving the access to novel treatments. We are fully supportive of the collaborative activities of the Canadian MPN group.”
Ms. Lisa Lacamell
Patient support Group Coordinator, Vancouver, BC
“As MPN patients, we are grateful for the focus and attention from MPN professionals. Thank you to Dr. Foltz and the newly formed Canadian MPN Group who are dedicating their efforts to improve care and research that will translate into better patient outcomes for all of us.”
ACADEMIA
Dr. Issac Odame, MD, FRCPC, FRCPath
Director, Division of Hematology
University of Toronto
Toronto, Ontario
“I applaud the Canadian MPN Group for launching this collaborative effort to promote access to quality comprehensive care for MPN patients and advance clinical and laboratory research in the field. Congratulations on this great achievement and I wish the Canadian MPN Group all the vey best for success!”
Dr. Shannon Bates, MDCM, MSc, FRCPC
Director, Division of Hematology
McMaster University, Hamilton
“Myeloproliferative neoplasms pose a particular challenge for physicians and affected patients. Although these cancers are rare, their incidence is increasing as the population ages. There are important gaps in our understanding of the causes, opportunities for prevention, and optimal treatment strategies for these conditions. Moreover, few physicians have had the chance to diagnose or provide care for a patient with a myeloproliferative neoplasm. Outside of specialists who treat these patients, most family physicians and many hematologists have no or little experience in caring for patients with myeloproliferative neoplasms. Consequently, patients may experience delayed diagnosis and may not receive the support or treatment that they need. Finally, there are very few organizations dedicated to myeloproliferative neoplasms and those that exist are often based in other countries and not attuned to the Canadian healthcare system and the needs of our healthcare providers and patients.
However, there is good news! Research is leading to improvements in the diagnosis and treatment of these cancers. A national network like the Canadian Myeloproliferative Neoplasm Group has a real opportunity to improve research into these conditions and the care of affected patients by promoting and facilitating collaborative research; patient access to high quality, effective care; patient and healthcare provider education and treatment guidelines.
I have no doubt that your group will make an important difference to the wellbeing of patients with myeloproliferative neoplasms. I am fully supportive of your exciting endeavour!”
Dr. Aaron Schimmer, MD, PhD, FRCPC
President, Canadian Hematology Society
“The Canadian Hematology Society is delighted to endorse the Canadian MPN group. Your group is comprised of internationally-recognized experts in the field of myeloproliferative disorders. The Canadian MPN group is making significant contributions to the diagnosis and treatment of this disorder. We are also pleased to note your collaborative efforts to bring together health care professionals interested in patient care, education, and research related to MPN. We wish you the best as your move forward with your endeavours.”